|
US2021007978A1
|
|
Fixed Dose Oral Testosterone Undecanoate Compositions and Use Thereof
|
|
WO2020018974A1
|
|
Liver disease
|
|
US2020069805A1
|
|
Pharmaceutical compositions with synchronized solubilizer release
|
|
CA3078724A1
|
|
Oral testosterone tridecanoate therapy
|
|
US2018147215A1
|
|
Oral testosterone undecanoate therapy
|
|
US2018153904A1
|
|
High-strength testosterone undecanoate compositions
|
|
US2017319596A1
|
|
Methods for improving quality of life or sexual domain function and composition useful in the methods
|
|
EP3310359A2
|
|
17-hydroxyprogesterone ester-containing oral compositions and related methods
|
|
US2016361322A1
|
|
Composition and method for oral delivery of androgen prodrugs
|
|
WO2016049382A1
|
|
Compositions and their use in oral dosing regimens
|
|
US2015374826A1
|
|
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
CN106999558A
|
|
Base undecylate composition of (17 β) 3 oxygen androstane-14 alkene 17 and its production and use
|
|
WO2016033549A2
|
|
(17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
|
AU2015308614A1
|
|
Pharmaceutical composition and methods
|
|
US2016184320A1
|
|
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
|
US2016367569A1
|
|
High-strength testosterone undecanoate compositions
|
|
US2015224059A1
|
|
High-strength testosterone undecanoate compositions
|
|
US2014303130A1
|
|
High-strength testosterone undecanoate compositions
|
|
US2014309202A1
|
|
High-strength testosterone undecanoate compositions
|
|
US2014288039A1
|
|
Lipobalanced long chain testosterone prodrugs for oral delivery
|
